8-K: Evoke Pharma Acquired by QOL Medical; Q3 Sales Up 61%

Evoke Pharma announced its acquisition by QOL Medical for $11.00 per share in cash, alongside reporting a 61% year-over-year increase in third-quarter net product sales.

Summary

• Evoke Pharma has entered into a merger agreement to be acquired by QOL Medical, LLC, for $11.00 per share in cash.
• Net product sales for the third quarter of 2025 reached $4.3 million, marking a 61% increase year-over-year.
• Year-to-date sales for 2025 totaled $11.1 million, a 60% increase compared to the same period in 2024.
• A new U.S. patent for GIMOTI (U.S. Patent No. 12,377,064) was granted in August 2025, extending its expected exclusivity to November 2038.
• Expanded pharmacy access for GIMOTI was announced through new relationships with Omnicell and Brentwood Pharmacy.
• The net loss for Q3 2025 was approximately $1.2 million, or ($0.45) per share, an improvement from a net loss of $1.3 million, or ($0.94) per share, in Q3 2024.
• Operating expenses for Q3 2025 increased to $5.4 million from $3.9 million in Q3 2024, primarily due to higher marketing and Eversana profit-sharing costs.
• As of September 30, 2025, cash and cash equivalents stood at $11.6 million, which, combined with projected product revenues, is expected to fund operations into the fourth quarter of 2026.

Sentiment

Score: 8

Explanation: The announcement of the acquisition at a specific cash price per share, combined with strong sales growth and patent extension, indicates a very positive outlook for shareholders, despite ongoing operational losses. The acquisition provides a clear exit strategy and value realization.

Positives

• Agreement to be acquired by QOL Medical for $11.00 per share in cash, representing a compelling opportunity for shareholders.
• Net product sales for Q3 2025 increased by 61% year-over-year to $4.3 million.
• Year-to-date sales increased by 60% to $11.1 million compared to the same period in 2024.
• GIMOTI patent life extended through November 2038 with U.S. Patent No. 12,377,064, enhancing long-term exclusivity.
• Expanded pharmacy access for GIMOTI through new relationships with Omnicell and Brentwood Pharmacy, enabling wider distribution.
• Net loss decreased to $1.2 million in Q3 2025 from $1.3 million in Q3 2024.
• Net loss per share significantly improved to ($0.45) in Q3 2025 from ($0.94) in Q3 2024.
• Cash balance of $11.6 million as of September 30, 2025, is projected to fund operations into Q4 2026.

Negatives

• Operating expenses increased to $5.4 million in Q3 2025 from $3.9 million in Q3 2024, primarily due to higher marketing and profit-sharing costs.
• The company still reported a net loss of $1.2 million for Q3 2025.

Risks

• Uncertainties as to the timing and completion of the tender offer and the merger.
• Uncertainties as to the percentage of Evoke's stockholders tendering their shares in the tender offer.
• The possibility that competing offers will be made.
• The possibility that various closing conditions for the tender offer or the merger may not be satisfied or waived.
• The effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors, and other business partners.
• Risks related to diverting management's attention from Evoke's ongoing business operations.
• The risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification, and liability.
• Evoke and EVERSANA may not be able to successfully drive market demand for GIMOTI.
• Evoke's ability to maintain intellectual property protection and regulatory exclusivity for GIMOTI.
• Other risks and uncertainties pertaining to Evoke's business, including those detailed in its periodic reports filed with the SEC.

Future Outlook

The company expects the acquisition by QOL Medical to close in the fourth quarter of 2025, subject to customary conditions. This transaction is anticipated to further enable growth potential for the GIMOTI franchise under new leadership and investment. The current cash balance, combined with projected product revenues, is expected to fund operations into the fourth quarter of 2026.

Management Comments

• "The proposed transaction with QOL Medical reflects this progress and the strategic value we've built around GIMOTI and across the broader GI community." Matt D'Onofrio, Chief Executive Officer of Evoke Pharma.
• "We are proud of the consistent execution that led to another quarter of strong sales growth, with net product sales up over 60% year-over-year." Matt D'Onofrio, Chief Executive Officer of Evoke Pharma.
• Evoke believes this transaction represents a compelling opportunity for shareholders and underscores the value created by the GIMOTI franchise.
• While the Company continues to focus on commercial execution in the near term, this proposed combination is expected to further enable growth potential under new leadership and investment.

Industry Context

Evoke Pharma operates in the specialty pharmaceutical sector, focusing on gastrointestinal disorders, specifically diabetic gastroparesis. GIMOTI, a nasal spray formulation of metoclopramide, is the only FDA-approved drug for this condition, offering a unique delivery method compared to traditional oral and injectable forms. The acquisition by QOL Medical suggests consolidation within the GI therapeutic area, potentially leveraging QOL Medical's resources for broader market penetration and development of the GIMOTI franchise. The patent extension further solidifies its market position against potential generic competition.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. Therefore, a detailed comparison is not possible based solely on this document.

Stakeholder Impact

• Shareholders: Will receive $11.00 per share in cash upon completion of the acquisition, representing a clear value realization.
• Employees: The transaction may cause disruption, making it more difficult to maintain relationships, and management's attention may be diverted from ongoing business operations.
• Customers: Expanded pharmacy access through Omnicell and Brentwood Pharmacy is expected to enable wider distribution of GIMOTI.
• Collaborators/Vendors: The transaction may cause disruption, making it more difficult to maintain relationships.

Next Steps

• QOL Medical's acquisition subsidiary will commence a tender offer to acquire all outstanding shares of Evoke.
• The transaction is expected to close in the fourth quarter of 2025, subject to customary conditions, including the tender of a majority of Evoke's outstanding shares.
• Evoke will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• QOL Medical and Merger Sub intend to file a Tender Offer Statement on Schedule TO with the SEC.

Key Dates

Recommendation

The definitive agreement for acquisition at $11.00 per share in cash provides a clear and immediate upside for current shareholders if the stock is trading below this price. The strong sales growth and patent extension for GIMOTI further validate the company's underlying asset value, making the acquisition price attractive. The unanimous board approval and expected Q4 2025 closing reduce uncertainty, making it a strong buy for investors looking to capture the acquisition premium.

Keywords

Evoke Pharma, EVOK, QOL Medical, GIMOTI, metoclopramide, diabetic gastroparesis, merger, acquisition, financial results, Q3 2025, patent extension, specialty pharmaceutical, GI disorders, nasal spray